Multiple myeloma case studies
Access the EMA Summary of Product Characteristics (SmPC) and FDA Prescribing Information (PI) for ciltacabtagene autoleucel. Adverse event reporting information can be found at the bottom of the page.
Patient case: Treatment selection in RRMM
Step into a strategic match where each move counts. Follow a real-world patient case, guided by a multiple myeloma (MM) expert, and consider what your next move would be as you complete the quizzes on MM management and treatment selection in people with relapsed/refractory MM (RRMM).
Patient profile: Consider your tactics
Video of KOL or figure introducing patient could be used here
Elena Zamagni introduces Lorenzo, a 70-year-old patient who remains physically active and has relapsed/refractory multiple myeloma. Lorenzo has undergone one previous line of therapy. Join the discussion as we review his clinical journey and consider optimal next steps for treatment selection, guided by expert insights in MM management.
What move would you make?
Examine the data and re-evaluate the position
[Video from Elena Zamagni]
Elena Zamagni outlines her primary considerations in selecting an appropriate second-line therapy for this patient, referencing the latest EHA-ESMO recommendations and emphasizing essential clinical data that inform her choice of treatment.
What move would you make?
Endgame: Patient outcomes
Elena Zamagni details the next steps in Lorenzo’s treatment journey, sharing the latest information on his response to therapy. She also explains how considering potential third-line options influenced her approach to selecting the most appropriate second-line regimen.
View the EHA 2025 symposium highlights for expert insights on selecting treatment regimens in patients with newly diagnosed MM.
Meet the expert
Elena Zamagni, MD, PhD
Elena Zamagni is Associate Professor of Hematology at the University of Bologna, Italy. Her research interests include areas related to MM, in particular on the role of high-dose therapy with stem cell support, of prognostic factors, minimal residual disease, novel therapies, and of imaging techniques.
Disclosures: [Disclosures included here].
Reporting suspected adverse reactions after authorization of the medicinal product is important. It allows continued monitoring of the benefit–risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via the national reporting system. Adverse events should also be reported to Johnson & Johnson. Please refer to the Summary of Product Characteristics (SmPC) or product information approved in your local country for further information.
This content has been sponsored by Johnson & Johnson. The content hosted on this platform is intended for educational purposes. Any data about non- Johnson & Johnson products are based on publicly available information. Prescribing information may vary depending on local health authority approval in each country. Before prescribing any product, always refer to the Summary of Product Characteristics (SmPC) or product information approved in your local country. This educational activity is intended for healthcare professionals only.
JOB CODE, DATE OF PREPARATION
of interest
are looking at
saved
next event